Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMicrosaic Regulatory News (MSYS)

Share Price Information for Microsaic (MSYS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.05
Bid: 1.00
Ask: 1.10
Change: 0.00 (0.00%)
Spread: 0.10 (10.00%)
Open: 1.05
High: 1.05
Low: 1.05
Prev. Close: 1.05
MSYS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - Microsaic Systems

10 Aug 2020 16:33

 

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser:

MD Barnard & Co Ltd

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

 

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Microsaic Systems PLC

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

 

(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

07th August 2020

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state “N/A”

N/A

 

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:

 

Ordinary 0.25p shares

 

 

Interests

Short positions

 

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

11,628,134

2.55

 

 

(2) Cash-settled derivatives:

 

 

 

 

 

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

 

 

 

 

 

TOTAL:

11,628,134

2.55

 

 

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:

N/A

Details, including nature of the rights concerned and relevant percentages:

N/A

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit

 

 

 

 

 

(b) Cash-settled derivative transactions

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

 

 

 

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

 

 

 

 

 

 

 

(ii) Exercise

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

 

 

 

(d) Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

 

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

 

NONE

 

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state “none”

 

NONE

 

(c) Attachments

Is a Supplemental Form 8 (Open Positions) attached?

NO

Date of disclosure:

10/08/2020

Contact name:

SIMON LIKE

Telephone number*:

02031795303

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel’s Market Surveillance Unit.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200810005522/en/

Copyright Business Wire 2020

Date   Source Headline
19th Feb 20197:00 amRNSNotice of Results
11th Jan 20197:00 amRNSNew Protein Identification Product
19th Dec 201811:20 amRNSBioprocessing partnership update & trading update
7th Nov 20187:00 amRNSExclusive US and Canada Distribution Agreement
3rd Sep 20187:00 amRNSInterim Results
7th Aug 20187:00 amRNSNotice of Results
29th Jun 20184:12 pmRNSHolding(s) in Company
26th Jun 20182:04 pmRNSHolding(s) in Company
25th Jun 201810:10 amRNSDirectors' Interests
22nd Jun 201810:40 amRNSResult of GM, Completion of Fundraising & TVR
21st Jun 20187:00 amRNSDistribution Agreement with Amedis, spol. s ro.
13th Jun 20187:00 amRNSDistribution Agreement with Omicron Research Ltd.
6th Jun 20187:00 amRNSSuccessful Fundraising of £5.5 million
5th Jun 20184:46 pmRNSPrimaryBid.com Offer
5th Jun 20184:45 pmRNSFundraising
24th May 20187:00 amRNSDistribution Agreement with Stable Arm Sdn. Bhd.
9th May 20187:00 amRNSAgreement with Rightek Co., Ltd.
4th May 201811:25 amRNSResult of AGM
4th May 20187:00 amRNSAGM Statement
12th Apr 20187:00 amRNSMicrosaic signs Agreement with Knauer
6th Apr 20187:00 amRNSNotice of AGM and Posting of Annual Report
28th Mar 20187:00 amRNSAgreement with Unimicro Technologies Inc.
23rd Mar 20184:45 pmRNSHolding(s) in Company
21st Mar 20187:00 amRNSCommercial contract with CPI Innovation Services
5th Mar 20187:00 amRNSFinal Results
21st Feb 20187:00 amRNSNotice of Results
3rd Jan 20187:00 amRNSAward of Options
19th Dec 20177:00 amRNSDirectorate Change
13th Dec 20177:00 amRNSResearch agreement with global biopharma partner
28th Sep 20177:00 amRNSInterim Results
25th Sep 20177:00 amRNSAppointment of CEO
13th Sep 20177:00 amRNSMicrosaic to Exhibit at BioProcess International
14th Aug 20177:00 amRNSNotice of Results
19th Jun 20177:00 amRNSTrading Statement
15th May 201711:42 amRNSResult of AGM
11th May 20177:00 amRNSMicrosaic Enhances Bioprocessing Capabilities
26th Apr 20177:00 amRNSIntegration with SCPA chromatography software
21st Apr 20177:00 amRNSNotice of AGM
7th Apr 20177:00 amRNSAgreement
21st Mar 20177:00 amRNSFinal Results
13th Mar 20177:00 amRNSChange of registrar
24th Jan 201712:56 pmRNSAppointment of Interim Chairman
13th Dec 20167:00 amRNSTrading Statement
28th Sep 20167:00 amRNSDirectorate Change
21st Sep 20164:39 pmRNSHolding(s) in Company
16th Sep 20161:44 pmRNSDirector/PDMR Shareholding
15th Sep 20161:03 pmRNSHolding(s) in Company
15th Sep 201610:02 amRNSTR-1: Notification of Major Interest in Shares
14th Sep 20165:23 pmRNSHolding(s) in Company
14th Sep 20163:38 pmRNSGrant of Options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.